Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies

Molecular Immunology

Volumn 44, Issue 7, 2007, Pages 1815-1817

  Nechansky, Andreas ^a   Schuster, Manfred ^b   Jost, Wolfgang ^c   Siegl, Petra ^a   Wiederkum, Susanne ^a   Gorr, Gilbert ^c   Kircheis, Ralf ^a  

^a Igeneon GmbH   (Austria)

^b Apeiron Biologics Forschungs und Entwicklungsgesellschaft MbH   (Austria)

^c Greenovation Biotech GmbH   (Germany)

Author keywords

ADCC; Effector function; Fc gamma RIII; Fucosylation; Glyco modification; Moss; Therapeutic antibody

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; IGN 311; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; FUCOSYLATION; HUMAN; HUMAN CELL; LETTER; PRIORITY JOURNAL; BINDING COMPETITION; CHEMISTRY; GLYCOSYLATION; IMMUNOLOGY; NOTE; PROTEIN CONFORMATION; PROTEIN ENGINEERING; TUMOR CELL LINE;

BRYOPHYTA;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BINDING, COMPETITIVE; CELL LINE, TUMOR; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECEPTORS, IGG;

EID: 33751322142     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.08.013     Document Type: Letter

References (13)

1. Deo Y.M., Graziano R.F., Repp R., and van de Winkel J.G. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol. Today 18 (1997) 127-135
2. Dettke M., and Loibner H. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro. Br. J. Cancer 82 (2000) 441-445
3. Harris L.J., Skaletsky E., and McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody. J. Mol. Biol. 275 (1997) 861-872
4. Jefferis R., Lund J., and Pound J.D. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 163 (1998) 59-76
5. Niwa R., Hatanaka S., Shoji-Hosaka E., Sakurada M., Kobayashi Y., Uehara A., Yokoi H., Nakamura K., and Shitara K. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgammaRIIIa functional polymorphism. Clin. Cancer Res. 10 (2004) 6248-6255
6. Niwa R., Shoji-Hosaka E., Sakurada M., Shinkawa T., Uchida K., Nakamura K., Matsushima K., Ueda R., Hanai N., and Shitara K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64 (2004) 2127-2133
7. Okazaki A., Shoji-Hosaka E., Nakamura K., Wakitani M., Uchida K., Kakita S., Tsumoto K., Kumagai I., and Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J. Mol. Biol. 336 (2004) 1239-1249
8. Preithner S., Elm S., Lippold S., Locher M., Wolf A., da Silva A.J., Baeuerle P.A., and Prang N.S. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol. Immunol. 43 (2006) 1183-1193
9. Radaev S., Motyka S., Fridman W.-H., Sautes-Fridman C., and Sun P.D. The structure of a human type III Fcγ receptor in complex with Fc. J. Biol. Chem. 276 (2001) 16469-16477
10. Schuster, M., Jost, W., Mudde, G.C., Wiederkum, S., Schwager, C., Janzek, E., Altmann, F., Stadlmann, J., Stemmer, C., Gorr, G., 2006. In vivo glyco-engineered antibody with improved lytic potential produced by a non-mammalien expression system. Plant Biotechnol. J., submitted for publication.
11. Schuster M., Umana P., Ferrara C., Brünker P., Gerdes C., Waxenecker G., Wiederkum S., Schwager C., Loibner H., Himmler G., and Mudde G.C. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res. 65 (2005) 7934-7941
12. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., and Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002) 26733-26740
13. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the Fcgamma R. J. Biol. Chem. 276 (2001) 6591-6604